Viracta Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Viracta Therapeutics

10/11/2022 23:02

* Viracta Therapeutics Inc  VIRX.OQ  reported a quarterly
adjusted
loss of 47 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Viracta Therapeutics Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Viracta Therapeutics Inc shares had fallen by 23.9% this
quarter and lost 11.0% so far this year.
    * The company reported a quarterly loss of $17.74 million.
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.30          -0.47          Missed
 Jun. 30 2022      -0.30          -0.28          Beat
 Mar. 31 2022      -0.31          -0.28          Beat
 Dec. 31 2021      -0.43          -0.31          Beat